The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019.
More than a third of the money raised through biopharma financings in 2020 was raised by companies developing either a therapeutic or a vaccine for COVID-19, yet completely wiping away those totals still leaves the year with $76.8 billion, a full 12% more than the next highest year.
Multiple companies have had their FDA reviews put on hold because coronavirus-related travel restrictions at the FDA has kept their manufacturing plants from being inspected.
Still not there yet, but close. Biopharma projected deal values are currently at $159.4 billion, just shy of the 2019 record of $160.3 billion. With about six weeks left in the year, it is highly likely that 2020 will come out on top.
RSS
